SCHEMBL89838

SCHEMBL89838

c1cc2cnsc2cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29998671 1.00
SCHEMBL88831 0.81
SCHEMBL30051093 0.81
Azetidine SCHEMBL20336251 0.71 ROCK1 (0.36)
SCHEMBL29355782 0.70
SCHEMBL22858 0.70
SCHEMBL2877030 0.70
Pyridine SCHEMBL28928518 0.70 TDO2 (0.37)
SCHEMBL4579663 0.68 SLC6A3 (0.38)
Hydrogen Sulfide SCHEMBL28558145 0.68 SLC6A3 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059745-A2 N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTAGONISTS AND USES THEREOF BEXSON BIOMEDICAL, INC. (US) 2024-03-21 WO claimed
US-20260124177-A1 CO-THERAPIES INCLUDING A METASTASIS INHIBITOR NOVITA PHARMACEUTICALS, INC. (US) 2026-05-07 US disclosed
EP-4735420-A1 ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-05-06 EP disclosed
EP-4727548-A1 METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20260098018-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS INC (US) 2026-04-09 US disclosed
US-12508245-B2 Co-therapies including a metastasis inhibitor NOVITA PHARMACEUTICALS, INC. (US) 2025-12-30 US disclosed
US-20250368657-A1 METHODS FOR INHIBITING FASCIN NOVITA PHARMACEUTICALS INC (US) 2025-12-04 US disclosed
US-20250368654-A1 HETEROCYCLIC INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
EP-4646401-A1 NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY CELON PHARMA S.A. (PL) 2025-11-12 EP disclosed
US-20250333411-A1 COMPOUNDS AND METHODS FOR INHIBITING FASCIN CORNELL UNIVERSITY (US) 2025-10-30 US disclosed
EP-1381366-B1 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2009-04-22 EP disclosed
US-20080242662-A1 Organic Compounds NIHONYANAGI ATSUKO 2008-10-02 US disclosed
US-20080194629-A1 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors BAESCHLIN DANIEL KASPAR 2008-08-14 US disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 US disclosed
US-20060040924-A1 Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of renal colic LABORATORIOS DR. ESTEVE S.A. (ES) 2006-02-23 US disclosed
EP-1381366-A4 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-02-16 EP disclosed
US-6825201-B2 ANTIVIRAL ACTIVITY; TREATMENT OF HIV AND AIDS BRISTOL-MYERS SQUIBB COMPANY 2004-11-30 US disclosed
EP-1381366-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-21 EP disclosed
US-20030096825-A1 Indole, azaindole and related heterocyclic amidopiperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-05-22 US disclosed
WO-2002085301-A2 INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC AMIDOPIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-31 WO disclosed